Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features

Mei, Yi; Cai, Dongyan; Dai, Xiaofeng

doi:10.7150/jca.37117



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2020; 11(5):1162-1169. doi:10.7150/jca.37117 This issue Cite

Research Paper

Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features

Yi Mei^2*, Dongyan Cai³, Xiaofeng Dai^1✉*

1. Wuxi School of Medicine, Jiangnan University, Wuxi, China
2. School of Biotechnology, Jiangnan University, Wuxi, China
3. Department of Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China
*co-first authors

Citation:

Mei Y, Cai D, Dai X. Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features. J Cancer 2020; 11(5):1162-1169. doi:10.7150/jca.37117. https://www.jcancer.org/v11p1162.htm

Other styles

Abstract

Breast cancers can be classified into luminal A, luminal B, HER2 positive and triple-negative subtypes, each with a distinct therapeutic response. Tumor stemness drives cancer malignancy that challenges cancer control. Understanding the revolutionary relationships driven by tumor stemness among breast cancer subtypes is fundamental to identifying feasible therapeutic modalities for each breast cancer subtype.

Utilizing the endogenous tRNA-processing system, we established a multiplexing CRISPR/dCas9 system in breast cancer cells, and applied it to a four-gene panel controlling cell potency, i.e., OCT4, KLF, MYC, SOX2. The stable cell strain, OKMS#1 was obtained through concomitantly over-expressing these genes in luminal A breast cancer cells. OKMS#1 cells showed increased invasion, proliferation and cancer stemness, shared similar drug response pattern with HER2 positive cells, and exhibited altered MAPK and enhanced NFkB signaling. This study contributes in providing an efficient multiplexing CRISPR/dCas9 system that enriches our genetic modulation tool box, and suggests that HER2 positive cells are potential progenitors of luminal A cells and that these two breast cancer subtypes may share similar treatment strategies once rewired between the two states. Our results also implicate that triple negative breast cancer cells, though sharing similar cancer stemness with HER2 positive cells, represent a distinct type of disease and require unique treatment solutions.

Keywords: breast cancer, cancer stemness, progenitor cells, CRISPR/dCas9, therapeutic modality

Citation styles

APA

Mei, Y., Cai, D., Dai, X. (2020). Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features. Journal of Cancer, 11(5), 1162-1169. https://doi.org/10.7150/jca.37117.

ACS

Mei, Y.; Cai, D.; Dai, X. Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features. J. Cancer 2020, 11 (5), 1162-1169. DOI: 10.7150/jca.37117.

NLM

CSE

Mei Y, Cai D, Dai X. 2020. Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features. J Cancer. 11(5):1162-1169.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.